KDR and neoplasm: It competitively inhibits the binding of PD-1 to its ligand PD-L1, thereby reversing PD-1/PD-L1-mediated immunosuppression, while concurrently blocking VEGF-A interaction with VEGFR2 to suppress tumor angiogenesis within the tumor microenvironment.